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          A
sthma affects over 300 million people worldwide, 
and its prevalence is increasing. Asthma is a 
complex disease characterized by airway hyperrespon-
siveness, variable airﬂ  ow obstruction, airway inﬂ  am-
mation, varying degrees of subepithelial ﬁ  brosis, mucus 
hyperproduction, and remodeling.   1    Atopic asthma 
has classically been associated with increased expres-
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  The OX40 receptor is preferentially expressed by T cells, and its cognate ligand OX40L is primarily 
expressed by antigen-presenting cells such as dendritic cells following activation by thymic stromal 
lymphopoietin (TSLP). TSLP is released by the bronchial epithelium, airway     smooth muscle, and 
some inﬂ  ammatory cells in response to numerous insults such as allergens, viruses, and physical 
damage. OX40L is a costimulatory molecule that plays a sentinel role in the adaptive immune 
response by promoting T helper (Th) 2 polarization of naive T cells within the lymph node. These 
polarized T cells produce Th2 cytokines such as IL-4, IL-5, and IL-13, which have been impli-
cated particularly in allergic eosinophilic asthma. Animal models have positioned both TSLP 
and OX40/OX40L as critical in the development of airway inﬂ  ammation and hyperreactivity. In 
human disease, there is good evidence that TSLP is upregulated in asthma, but there are limited 
data to demonstrate overexpression of OX40 or OX40L in disease. Targeting the OX40/OX40L 
axis or TSLP presents a novel therapeutic strategy that has the potential of modifying the disease 
process and, therefore, impacting on its natural history. Whether this approach can demonstrate 
efﬁ  cacy in established disease rather than at disease onset is unknown. Biologic therapies directed 
toward OX40/OX40L are in early phases of development, and results from these studies are eagerly 
awaited.          CHEST 2012; 141(  2  ):  494  –  499   
    Abbreviations    :      Nod   5    nucleotide-binding  oligomerization  domain    ;     Th   5    T  helper    ;     TNF   5    tumor  necrosis  factor    ; 
   TSLP   5    thymic  stromal  lymphopoietin     
sion of T helper (Th) 2 cytokines, which are increased 
in sputum,   2    bronchoalveolar T cells,   3    and bronchial 
biopsies.   4    A major effector axis resulting in induction 
of Th2 polarization is the recognition of allergen pre-
sented by dendritic cells in local lymph nodes to CD4    1   
T cells. This axis is an optimal target for drug devel-
opment because it orchestrates the inﬂ  ammation and 
development of an allergen-speciﬁ  c humoral response 
and the development of T- and B-cell memory. The 
differentiation of naive T cells or reactivation of memory 
T cells depends on various costimulatory molecules 
primarily expressed on the surface of T cells and their 
cognate ligands. One of the most promising costimu-
latory targets is OX40 and its ligand, OX40L. OX40L 
is directly mediated by thymic stromal lymphopoietin 
(TSLP), which is produced by epithelial cells,   5    mast 
cells,   6   airway smooth muscle,   7   and dendritic cells,   8   which 
are all involved in Th2 responses. TSLP was originally 
identiﬁ  ed as a growth-promoting factor found in cul-
tured supernatants of a thymic stromal cell line in 
1994 to support the development of murine B cells.   9   
TSLP plays an important role in many allergic diseases, CHEST / 141 / 2 / FEBRUARY, 2012    495 www.chestpubs.org
such as atopic dermatitis and asthma. TSLP is also 
up-regulated in COPD,   10    but its role and relationship 
to OX40/OX40L signaling in this disease is unclear. 
TSLP binds to its TSLP receptor and the IL-7 
receptor   a   chain. Dendritic cells play a crucial role 
in the pathogenesis of allergic disease. TSLP activates 
immature CD11c    1    dendritic cells to express OX40L, 
and these cells then become mature dendritic cells, 
which migrate to the draining lymph nodes. There 
they activate the differentiation of naive CD4  1  
T cells by binding to the OX40 receptor, where they 
become inﬂ  ammatory cells producing IL-4, IL-5, 
IL-13, tumor necrosis factor-  a   (TNF- a  ), and little or 
no IL-10 (  Fig 1  ).   11       
  The sentinel roles of the OX40/OX40L axis in the 
adaptive immune response and TSLP in both the 
innate and adaptive responses suggest these molec-
ular targets may present attractive novel therapeutic 
targets. In this article, we consider the evidence that 
   
 Figure  1  .         Drawing shows the pathophysiologic characteristics of OX40/OX40L and TSLP in allergic 
inﬂ  ammation. Cellular damage caused by allergens or viruses triggers mucosal epithelial cells or skin 
cells (keratinocytes, ﬁ  broblasts, and mast cells) to produce TSLP. TSLP initiates the innate phase of 
allergic immune responses by activating immature DCs by binding to their TSLPR. TSLP/TSLPR-
activated DCs produce the chemokines IL-8 and eotaxin-2, TARC, and MDC, and by costimulating 
mast cells, produce IL-5, IL-13, GM-CSF, and IL-6. The activated immature DCs then mature and pro-
duce the OX40L and migrate into the draining lymph nodes, where they trigger the differentiation of 
allergen-speciﬁ  c naive CD4    1    T cells by binding to the receptor OX40 and differentiating the CD4    1   
T cells into inﬂ  ammatory Th2 cells, producing IL-4, IL-5, IL-13, and TNF- a , but no IL-10. These Th2 cyto-
kines then initiate inﬂ  ammation by triggering IgE production, eosinophilia, mucus production, and ﬁ  bro-
blast proliferation. DC   5   dendritic cell; GM-CSF   5   granulocyte-macrophage colony-stimulated factor; 
MDC  5   macrophase-derived chemokine; MHC   5   major histocompatibility complex; TARC   5  T-helper 
2 attracting chemokines activation-regulated chemokine; Th   5  T-helper; TNF  5   tumor necrosis factor; 
TSLP  5   thymic stromal lymphopoietin; TSLPR   5  thymic  stromal  lymphopoietin  receptor.      
the OX40/OX40L axis plays a role in asthma, its 
potential importance as a therapeutic target, and the 
likely target population.   
 OX40 and OX40L 
  OX40 (ACT35, CD134, TNFRSF4) was identiﬁ  ed 
in 1987 and found to be bound to activated T cells.   12   
Since then, it has been cloned in rat, mouse, and 
human cells. The OX40 receptor is preferentially 
expressed on the surface of activated regulatory CD4    1   
T cells,   13    natural killer T cells, natural killer cells, and 
neutrophils, and more recently, we have found it to 
be expressed in human airway smooth muscle cells.   14   
OX40 signaling strongly regulates T-cell division, 
survival, and cytokine release.   15    The OX40 ligand 
(OX40L, CD252, TNFSF4) was originally identiﬁ  ed 
in 1985 as gp34 (GP34) protein on human T cell leu-
kemic virus-transformed cells   16    and is expressed on 496 Translating Basic Research Into Clinical Practice
antigen-expressing cells, for instance, B cells,   17    den-
dritic cells,   18    and macrophages   19    as well as airway 
smooth muscle cells.   20     
  Evidence of a Critical Role for OX40/OX40L 
in the Pathogenesis of Asthma   
 Animal  Models 
  In murine asthma models, OX40    2 / 2    mice chal-
lenged with ovalbumin showed signiﬁ  cantly reduced 
Th2 response, lung inﬂ  ammation, mucus secretion, 
80% to 90% reduction in eosinophilia, decreased 
goblet cell hyperplasia, and signiﬁ  cantly attenuated 
airway hyperreactivity compared with wild-type mice.   21   
Studies have also demonstrated that OX40L    2 / 2    mice 
sensitized with ovalbumin have signiﬁ  cantly reduced 
total serum IgE, pulmonary eosinophils, cytokines, 
and pulmonary inﬂ  ammation compared with wild-
type control mice.   22 , 23    Inhibition of OX40-OX40L 
binding via the administration of anti-OX40L mAb in 
wild-type mice dramatically reduced airway hyperre-
sponsiveness and associated asthma symptoms, com-
pared with mice challenged with isotype control.   23 , 24   
Mouse splenic CD11c    1    dendritic cells stimulated for 
48 h with TSLP upregulated OX40L expression 
compared with CD40L or TNF-  a   and unstimulated 
cells. A blockade of OX40/OX40L interactions using 
a speciﬁ  c   a  -mouse OX40L 4F5 monoclonal anti-
body signiﬁ  cantly inhibited Th2 cytokine production 
compared with a control antibody. This conﬁ  rms that 
OX40L activity on dendritic cells was important for 
the effects of TSLP in driving Th2 polarization.   25   
Both in murine and nonhuman primate models of 
asthma in vivo, a blockade of OX40L inhibited TSLP-
mediated Th2 inﬂ  ammation.   25    Studies have demon-
strated that OX40 can inhibit the development of 
adaptive Foxp3    1    T regulatory cells that differentiate 
from naive CD4 T-cell populations in response to 
TGF-  b .  26 , 27    Foxp3, an X chromosome-encoded fork-
head transcription factor family member, is critical 
for the differentiation of regulatory T cells. These cells 
have an important role in preventing autoimmunity 
and pathologic changes inﬂ  icted by uncontrolled 
immune responses to infections. Deﬁ  ciency or muta-
tion in Foxp3 in humans and mice leads to early onset 
and susceptibility to diseases such as asthma.   28   
  Targeting OX40L may have the potential to 
improve the efﬁ  cacy of immunotherapy to promote 
tolerance. In wild-type mice exposed to intranasal 
antigen and speciﬁ  c CD4    1  Foxp3   1   , regulatory T cells 
were generated, which outnumbered IL-4 and inter-
feron   g  -producing CD4 T cells. Inhaled lipopolysac-
charide downregulated the regulatory T cells, but 
up-regulated IL-4    1    and interferon-  g   T cells, and it 
also increased OX40L expression on dendritic cells 
and B cells. Inhibiting OX40/OX40L interactions with 
an anti-OX40L antibody upregulated regulatory 
T cells suppressing lipopolysaccharide stimulation.   29   
  Sensitization to fungi such as   Aspergillus fumigatus  
and   Alternaria   is associated with poor lung function   30   
and exacerbations. When bone marrow-derived mouse 
dendritic cells were stimulated with   Alternaria   for 
48 h, upregulation in OX40L expression was detected 
using ﬂ  ow cytometry,   31    suggesting that   Alternaria  
may play a role in Th2 cytokine release. 
  The activation of pattern-recognition receptors such 
as toll-like receptors plays a critical role in Th1 cell 
differentiation, yet their contri  bution to the genera-
tion of Th2 responses is poorly understood. Interest-
ingly, when mice deﬁ  cient in either MyD88    2 / 2    or 
TLR4    2 / 2    were sensitized intranasally to the common 
allergen house dust mites and challenged 2 weeks 
later, they showed diminished Th2 responses as well 
as fewer OX40Ls presenting dendritic cells in the 
draining lymph node compared with wild-type mice.   32   
The activation marker CD30, a member of the TNF 
receptor family, is expressed on activated T cells. In 
an acute asthma model, CD30    2 / 2    mice developed 
reduced expression of OX40,   33    whereas in contrast, 
OX40 expression was not downregulated in a chronic 
murine asthma model.   34    These differences in expres-
sion may be the result of the fact that in a chronic 
asthma model, T cells are able to proliferate, leading 
to chronic airway inﬂ  ammation. Airway tolerance is 
vital for protecting the lung from inﬂ  ammatory dis-
ease-driven allergens, but factors that lead to this sus-
ceptibility remain elusive. The pattern recognition 
receptors nucleotide-binding oligomerization domain 
(Nod)-like receptors Nod1 and Nod2 are both highly 
expressed by epithelial cells. Intranasal exposure of 
Nod2, but not Nod1, induced TSLP-promoting OX40L 
expression. The generation of these ligands also 
blocked CD4    1    fork-head box protein 3    1    adaptive reg-
ulatory T cells and concomitantly drove IL-4-producing 
CD4 T cells, leading to allergic disease and asthmatic 
lung inﬂ  ammation.   35   
  The animal-model data, therefore, present com-
pelling evidence of a central role for OX40/OX40L in 
the development of Th2 polarization in response to a 
number of insults that are considered important in 
asthma. These data support a role for this axis in the 
immunopathogenesis of asthma.     
 Human  Models 
  The role of OX40/OX40L in humans is limited 
compared with murine-model systems. TSLP was 
preferentially induced in peripheral blood-isolated 
myeloid dendritic cells from healthy volunteers to 
express mRNA for OX40L using microarray analysis.   11   
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OX40L-neutralizing antibody inhibited the produc-
tion of Th2 cytokines and TNF-  a  , but increased the 
production of IL-10 in CD4    1    cells cocultured with 
TSLP-primed dendritic cells.   11   Airway smooth muscle 
cells are critical in the development of bronchocon-
striction in asthma, are the major contributors to 
airway remodeling and persistent airﬂ  ow obstruc-
tion, and release a number of chemokines/cyto-
kines that bind speciﬁ   cally to activated T cells, 
resulting in increased cellular proliferation. Studies 
have reported OX40L to be expressed and released by 
airway smooth muscle cells of people with and with-
out asthma, but with no signiﬁ  cant difference.   20   How-
ever, following TNF-  a   stimulation, there was an 
increase in OX40L, and a decrease after stimulation of 
TNF-  a   and interferon-  g   combined.  36    Cells activated 
with rOX40:Fc over 24 h released IL-6, which was 
signiﬁ  cantly higher in the patients with asthma com-
pared with people without asthma.   36    More recently, 
our group has reported OX40/OX40L expression to 
be increased in the bronchial submucosa of patients 
with mild asthma, but not in those with moderate to 
severe disease, and this was related to the degree 
of tissue eosinophilia and IL-4 expression.   14   
  Air pollution, particularly from diesel-exhaust par-
ticulates, is associated with worsening in asthma sym-
ptoms and control. Bronchial epithelial cells are the 
ﬁ  rst major targets for inhaled pollutants. Bronchial 
epithelial cells treated with diesel-exhaust particulates 
express an increase in OX40L expression.   37    A recent 
study also identiﬁ  ed TSLP to be highly expressed in 
isolated nasal epithelial cells from patients with nasal 
polyposis compared with those without. The TSLP 
receptor and OX40L receptor were also increased 
in dendritic cells from the nasal mucosa of patients 
with nasal polyposis.   38   
  The evidence in humans of a role of OX40/OX40L 
in asthma is, therefore, circumstantial and the expres-
sion data are weak. However, the interaction between 
OX40/OX40L in Th2 polarization may occur early in 
the disease pathogenesis and, more importantly, is 
primarily located in the lymph node rather than the 
bronchial submucosa. Current strategies to explore 
this axis have not addressed this compartment, and, 
therefore, its role has not been fully studied.       
 TSLP  Asthma 
 TSLP is both necessary and sufﬁ  cient for the devel-
opment of Th2 cytokine-associated inﬂ  ammation of 
the airways in rodents. Mice expressing a TSLP 
transgene in the airway epithelium develop a spon-
taneous, progressive inﬂ  ammatory disease with all the 
characteristics of human asthma,   39    whereas direct 
intranasal delivery of TSLP (in the presence of antigen) 
leads to rapid onset of features similar to severe 
disease.   40    Studies have also reported increased TSLP 
mRNA in bronchial epithelium in asthma in response 
to allergen, viruses, and other environmental stimuli.   41   
In human disease, genetic analysis has shown an asso-
ciation of polymorphisms in   TSLP   with asthma and 
airway hyperresponsiveness, IgE concentrations, and 
eosinophilia.   42 - 44    In addition, patients with asthma 
have higher concentrations of TSLP in their lungs.   45 , 46   
The role of TSLP in both the innate and adaptive 
immune response may suggest that its potential efﬁ  -
cacy is broader than targeting the OX40/OX40L axis 
alone.   
  Targeting the TSLP and OX40/OX40L Axis 
in Asthma 
  There is an increasing recognition that asthma 
is a heterogeneous condition.   47    Complex gene-
environment interactions activate several biologic 
pathways that consequently result in the disordered 
airway physiologic aspects and symptoms that charac-
terize asthma. The view that asthma is primarily 
an allergic disease mediated by Th2 cytokines has 
been challenged because asthma can develop in the 
absence of atopy. Indeed, allergic sensitization is likely 
to be more important in early-onset disease and par-
ticularly in children, whereas this feature of disease 
is less prominent in late-onset asthma.   48    The appli-
cation of noninvasive measures of airway inﬂ  amma-
tion has also led us to observe different inﬂ  ammatory 
phenotypes, including eosinophilic- and neutrophilic-
predominant asthma.   49    The OX40/OX40L axis is par-
ticularly important in allergic sensitization and Th2 
polarization. Therefore, predictably, patients with 
Th2-mediated eosinophilic inﬂ  ammation are likely to 
be the most appropriate target population. However, 
the timing of the intervention is important and may 
be most effective prior to the onset of allergic sensiti-
zation and disease presentation, which obviously is 
unpredictable, and hence this is not a practical strat-
egy. Ongoing activation of the OX40/OX40L axis may 
be important is some patients with asthma, but to 
date, this is uncertain and biomarkers to identify this 
group are unknown. At present, one clinical trial has 
been completed using a huMAb OX40L in the pre-
vention of allergen-induced airway in adults with mild 
asthma. This study was funded by Genentech and 
completed in January 2011. However, the report from 
this study is still awaited.   50   
  TSLP is likely to be effective in the same popula-
tion as for OX40/OX40L, but also is critical in the 
innate immune response, suggesting its potential efﬁ  -
cacy may target a broader group of patients with 
asthma. Critically, the potential efﬁ  cacy of either 
approach will need to outweigh the potential side 498 Translating Basic Research Into Clinical Practice
effects. Importantly, to date, early safety studies sug-
gest that the safety proﬁ  le of anti-OX40 therapy is 
good.   
 Conclusion 
  Current asthma therapies improve symptoms, 
improve disease control, and reduce exacerbations.   1   
None are disease modifying whereby they alter the 
natural history of the underlying disease. Data from 
animal models present a compelling argument that 
targeting the TSLP or OX40/OX40L axis will alter 
allergic sensitization and T-cell polarization. This pre-
sents a tantalizing possibility that this therapeutic 
approach in asthma may be disease modifying. Patients 
with asthma and researchers share the ambition to 
achieve a cure for asthma that can only be achieved 
by disease modiﬁ  cation. Therefore, targeting TSLP 
or the OX40/OX40L axis presents an exciting oppor-
tunity that may provide a step-change in the treatment 
of asthma. Its fate will become apparent over the 
forthcoming couple of years as the eagerly awaited 
clinical  trials  are  reported.     
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